Skip to main content

Table 3 Clinicopathologic characteristics of 1184 cases of lymph node negative ER+/HER2- breast cancer with RS < 18, treated with endocrine therapy only (all percentages within columns)

From: Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

  RS 0–10 (n = 462) RS 11–17 (n = 722) Total (n = 1184)
RS: Mean, median (range) 7, 8 (0–10) 14, 14 (11–17) 11, 12 (0–17)
Age at diagnosis
 Mean, median (range); years 58, 59 (25–84) 58, 57 (22–90) 58, 58 (22–90)
  < 40 years; n (%) 19 (4.1%) 21 (2.9%) 40 (3.4%)
  40–49 years; n (%) 98 (21.2%) 156 (21.6%) 254 (21.5%)
  ≥ 50 years; n (%) 345 (74.7%) 545 (75.5%) 890 (75.2%)
Tumor size, median (range); cm 1.28, 1.1 (0.35–5.5) 1.28, 1.1 (0.3–4.5) 1.28, 1.1 (0.3–5.5)
Multifocality; n (%) 106 (22.9%) 128 (17.7%) 234 (19.8%)
LVI; n (%) 72 (15.6%) 126 (17.5%) 198 (16.7%)
Local treatment; n (%)
 BCS only 12 (2.6%) 28 (3.9%) 40 (3.4%)
 BCS and radiation therapy 301 (65.2%) 515 (71.3%) 816 (68.9%)
 Total mastectomy 149 (32.3%) 177 (24.5%) 326 (27.5%)
 Total mastectomy and radiation therapy 0 2 (0.3%) 2 (0.2%)
LRR; n (%) 3 (0.6%) 5 (0.7%) 8 (0.7%)
Median follow-up (range); months 51.7 (0.9–108.3) 51.3 (1–93) 51.4 (0.9–108.3)
  1. BCS breast conserving surgery, LRR locoregional recurrence, LVI lymphovascular invasion, RS recurrence score